Artelo Biosciences received a Nasdaq letter on April 6 2026 confirming that the company has met the Equity Rule and the Annual Shareholders Meeting Rule, thereby restoring its compliance status after a March 30 2026 private placement and a 3‑for‑1 reverse stock split that were undertaken to cure an equity deficiency.
The Nasdaq notice states that Artelo’s stockholders’ equity now satisfies the $2.5 million minimum required for continued listing, and that the company will remain under a mandatory panel monitor for one year. The letter also removes the immediate risk of delisting and preserves the company’s access to its Equity Line of Credit with Square Gate Capital.
Prior to the compliance fix, Artelo’s financial statements showed a $652,000 equity balance in the quarter ended March 31 2025 and a $1.272 million stockholders’ deficit as of December 31 2025, prompting an auditor’s going‑concern warning. The March 30 private placement raised approximately $11 million, and the reverse split became effective on March 10 2026. In addition to the equity raise, the company has an equity line of credit that could provide up to $50 million and has issued bridge notes totaling $310,000 to support ongoing operations.
President and Chief Executive Officer Gregory D. Gorgas said, "We are pleased to have regained compliance with Nasdaq's continued listing requirements."
With the delisting threat removed, Artelo can concentrate on advancing its pipeline, notably the ART27.13 program for cancer‑related anorexia and cachexia syndrome and the ART26.12 program for neuropathic pain. The company is also pursuing partnership negotiations that could provide non‑dilutive funding and strategic support. However, the company’s financial position remains fragile, and it must continue to meet Nasdaq’s ongoing compliance obligations while managing its cash burn and financing needs.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.